Clinical Trials

300 enrolled

Multiple Myeloma, Recurrence

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Enrolling by invitation

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

21 enrolled

Multiple Myeloma

NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

260 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT07150091 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM

20 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

14 enrolled

Multiple Myeloma

NCT06087653 2025-06-19

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

24 enrolled

Multiple Myeloma

NCT02649790 2025-03-19

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

GastrointestinalMyeloidOther hematologic neoplasmPlasma cell

277 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03544281 2025-03-18

DREAMM 6

153 enrolled 91 charts

Multiple Myeloma

NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

103 enrolled 21 charts

Phase 1/2 Active not recruiting

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT01084252 2024-11-01

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Other hematologic neoplasm

351 enrolled 56 charts

Hematologic Neoplasms

NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

17 enrolled 10 charts

Multiple Myeloma

NCT02348216 2024-06-04

ZUMA-1

307 enrolled 41 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05647512 2023-11-18

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

45 enrolled

Multiple Myeloma, Recurrence

NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

108 enrolled

Amyloidosis, Multiple Myeloma

NCT02685826 2023-10-06

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

56 enrolled 38 charts

Multiple Myeloma

NCT05205252 2023-08-15

ARIA

Other hematologic neoplasm

Hematologic Neoplasms

NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

40 enrolled 37 charts

EndocrineNET

Neuroendocrine Tumors

NCT01348919 2023-06-28

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

11 enrolled 15 charts

Multiple Myeloma, Neoplasms

NCT01794520 2023-04-10

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

117 enrolled 29 charts

Multiple Myeloma

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

50 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT02389543 2023-01-26

SLAM

Multiple Myeloma, Recurrence

NCT03481556 2022-12-19

ANCHOR

56 enrolled 22 charts

Multiple Myeloma

NCT01881789 2022-11-14

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

22 enrolled 17 charts

Multiple Myeloma

NCT01677858 2022-09-23

CHAMPION 1

116 enrolled 28 charts

Multiple Myeloma

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

136 enrolled

Multiple Myeloma

NCT01455389 2022-03-02

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01962792 2021-12-21

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

84 enrolled 14 charts

Multiple Myeloma

NCT01421186 2021-11-16

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

91 enrolled 19 charts

Multiple Myeloma

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Lymphoid

Lymphoma, B-Cell

NCT00708292 2020-12-17

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

29 enrolled